Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus.

PloS one - 1 Jan 2011

Hoopes Justin D, Driebe Elizabeth M, Kelley Erin, Engelthaler David M, Keim Paul S, Perelson Alan S, Rong Libin, Went Gregory T, Nguyen Jack T

Abstract excerpt

Widespread resistance among circulating influenza A strains to at least one of the anti-influenza drugs is a major public health concern. A triple combination antiviral drug (TCAD) regimen comprised of amantadine, oseltamivir, and ribavirin has been shown to have synergistic and broad spectrum activity against influenza A strains, including drug resistant strains. Here, we used mathematical modeling along with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amantadine
Share to Dogs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Influenza A virus

Share to Oseltamivir

Share to Ribavirin

Share to Serial Passage

Share to Suppression, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 22220216
DOI: 10.1371/journal.pone.0029778
PMCID: PMC3248427

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus.PMID 22220216Read ↗

Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.Semantic proximity Read ↗

Combination antiviral therapy for influenza: predictions from modeling of human infections.Semantic proximity Read ↗

Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms.Semantic proximity Read ↗

Popular Influenza Antiviral Drugs: Mechanisms, Efficacy, and ResistanceSemantic proximity Read ↗

Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010.Semantic proximity Read ↗

In vitro system for modeling influenza A virus resistance under drug pressure.Semantic proximity Read ↗

Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants.Semantic proximity Read ↗

[Drug-resistant influenza viruses: an overview].Semantic proximity Read ↗

Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations.Semantic proximity Read ↗

Frequency of Amantadine-Resistant Influenza A Viruses during Two Seasons Featuring Cocirculation of H1N1 and H3N2Semantic proximity Read ↗

Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs.Semantic proximity Read ↗

Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.